News | February 10, 2024
Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Combines biocompatibility, heat-resistance, transparency and durability
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
An accomplished R&D leader and champion of the application of AI to drug discovery
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Subscribe To Our Newsletter & Stay Updated
